AbbVie shares slide on sliding Humira revenue; Deerfield is making a big investment in new device startups
→ AbbVie triggered alarm bells on Wall Street today as the pharma company cited biosimilar competition in Europe for a steep decline in expected …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.